Hadrontherapy for Thymic Epithelial Tumors: Implementation in Clinical Practice.
carbon ion therapy
hadrontherapy
proton therapy
thymic carcinoma
thymoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
07
2021
accepted:
21
09
2021
entrez:
28
10
2021
pubmed:
29
10
2021
medline:
29
10
2021
Statut:
epublish
Résumé
Radiation therapy is part of recommendations in the adjuvant settings for advanced stage or as exclusive treatment in unresectable thymic epithelial tumors (TETs). However, first-generation techniques delivered substantial radiation doses to critical organs at risk (OARs), such as the heart or the lungs, resulting in noticeable radiation-induced toxicity. Treatment techniques have significantly evolved for TET irradiation, and modern techniques efficiently spare normal surrounding tissues without negative impact on tumor coverage and consequently local control or patient survival. Considering its dosimetric advantages, hadrontherapy (which includes proton therapy and carbon ion therapy) has proved to be worthwhile for TET irradiation in particular for challenging clinical situations such as cardiac tumoral involvement. However, clinical experience for hadrontherapy is still limited and mainly relies on small-size proton therapy studies. This critical review aims to analyze the current status of hadrontherapy for TET irradiation to implement it at a larger scale.
Identifiants
pubmed: 34707989
doi: 10.3389/fonc.2021.738320
pmc: PMC8543015
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
738320Informations de copyright
Copyright © 2021 Loap, Vitolo, Barcellini, De Marzi, Mirandola, Fiore, Vischioni, Jereczek-Fossa, Girard, Kirova and Orlandi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Radiother. 2021 Jun;25(4):358-365
pubmed: 33676830
Cancer Radiother. 2020 Oct;24(6-7):687-690
pubmed: 32753239
Front Immunol. 2020 Jan 15;10:3118
pubmed: 32010151
Med Phys. 2019 Sep;46(9):4116-4126
pubmed: 31220360
Radiother Oncol. 2020 May;146:213-220
pubmed: 32222489
Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):813-818
pubmed: 33190969
Ann Oncol. 2015 Sep;26 Suppl 5:v40-55
pubmed: 26314779
Oncotarget. 2019 Feb 12;10(13):1306-1319
pubmed: 30863491
Radiother Oncol. 2010 Apr;95(1):73-8
pubmed: 19800142
Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):793-8
pubmed: 10837966
Cancers (Basel). 2020 Oct 17;12(10):
pubmed: 33080914
J Med Imaging Radiat Oncol. 2021 Jun;65(3):337-344
pubmed: 33773081
J Clin Oncol. 2010 Aug 10;28(23):3746-53
pubmed: 20625125
Radiother Oncol. 2013 Jun;107(3):267-73
pubmed: 23759662
Tumori. 2021 Jun 22;:3008916211023154
pubmed: 34156895
Rare Tumors. 2014 May 13;6(2):5177
pubmed: 25002943
Clin Lung Cancer. 2021 Sep;22(5):469-472
pubmed: 33736940
Radiother Oncol. 2020 Dec;153:146-154
pubmed: 33007352
Transl Lung Cancer Res. 2018 Apr;7(2):106-113
pubmed: 29876309
J Thorac Oncol. 2013 May;8(5):e38-40
pubmed: 23584300
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S137-42
pubmed: 25396311
Theor Biol Med Model. 2011 Jul 26;8:27
pubmed: 21791103
Acta Oncol. 2017 Aug;56(8):1060-1064
pubmed: 28338373
Tumori. 2017 May 12;103(3):217-222
pubmed: 28291902
Cancer Sci. 2018 May;109(5):1562-1569
pubmed: 29498145
Radiat Oncol. 2016 May 17;11:68
pubmed: 27185038
Front Oncol. 2016 Jan 08;5:294
pubmed: 26779439
Acta Oncol. 2005;44(8):836-49
pubmed: 16332591
Radiother Oncol. 2003 Jun;67(3):265-74
pubmed: 12865174
Acta Oncol. 2019 Jul;58(7):1036-1040
pubmed: 30784340
Acta Oncol. 2018 Dec;57(12):1713-1720
pubmed: 30264630
Clin Lung Cancer. 2016 Sep;17(5):362-366
pubmed: 27372386
J Cancer Res Clin Oncol. 2020 Sep;146(9):2267-2276
pubmed: 32514629
Eur J Heart Fail. 2021 Jan;23(1):195-196
pubmed: 33179329
Cancer Radiother. 2021 Jul 15;:
pubmed: 34275748
J Thorac Dis. 2020 Dec;12(12):7635-7641
pubmed: 33447455
Am J Transl Res. 2020 May 15;12(5):2234-2240
pubmed: 32509215
Acta Oncol. 2021 May;60(5):649-652
pubmed: 33629926
Br J Radiol. 2020 Mar;93(1107):20190224
pubmed: 31317768
Cancer Radiother. 2021 Apr;25(2):119-125
pubmed: 33676829
Int J Part Ther. 2018 Winter;4(3):23-32
pubmed: 30079369
Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):267-272
pubmed: 32861818
Int J Part Ther. 2020 Nov 16;7(3):65-70
pubmed: 33604417
Anticancer Res. 2019 Sep;39(9):4613-4617
pubmed: 31519558
Eur J Cancer. 2008 Jan;44(1):123-30
pubmed: 18068351
J Thorac Oncol. 2010 Sep;5(9):1454-60
pubmed: 20651611
Phys Med Biol. 2008 Mar 21;53(6):1729-50
pubmed: 18367800
Radiother Oncol. 2016 Mar;118(3):504-9
pubmed: 26895711
Adv Radiat Oncol. 2019 Jan 17;4(1):63-69
pubmed: 30706012
J Clin Oncol. 2016 Jan 20;34(3):235-43
pubmed: 26573075
Nucl Med Mol Imaging. 2010 Sep;44(3):177-84
pubmed: 24899947
Ann Thorac Surg. 2011 Jan;91(1):219-25
pubmed: 21172516
J Thorac Oncol. 2018 Aug;13(8):1204-1212
pubmed: 29702286
Phys Med. 2019 Jan;57:215-220
pubmed: 30661743
Phys Med. 2019 Apr;60:120-126
pubmed: 31000071
Mediastinum. 2019 Sep;3:
pubmed: 31608320
Radiother Oncol. 2013 Nov;109(2):256-61
pubmed: 24183064
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):427-433
pubmed: 28871993
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
Acta Radiol. 2021 Apr;62(4):557-564
pubmed: 32551804